Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients
Aim: The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug‐resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children. Methods: Pediatric patients hospitalized at the Uludag Univers...
Gespeichert in:
| Veröffentlicht in: | Pediatrics international 2010-06, Vol.52 (3), p.410-414 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 414 |
|---|---|
| container_issue | 3 |
| container_start_page | 410 |
| container_title | Pediatrics international |
| container_volume | 52 |
| creator | Celebi, Solmaz Hacimustafaoglu, Mustafa Koksal, Nilgun Ozkan, Hilal Çetinkaya, Merih |
| description | Aim: The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug‐resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children.
Methods: Pediatric patients hospitalized at the Uludag University Hospital who had nosocomial infections caused by multidrug‐resistant P. aeruginosa or A. baumannii, were enrolled in the study. Colistimethate sodium at a dosage of 50–75 × 103 U/kg per day was given i.v. divided into three doses.
Results: Fifteen patients received 17 courses of colistimethate sodium for the following infections: ventilator‐associated pneumonia (n= 14), catheter‐related sepsis (n= 1) and skin and soft‐tissue infection (n= 2). The mean age of patients was 53.2 + 74.7 months (range, 8 days–15 years) and 60% were male. Mortality was 26.6%.
Conclusion: Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug‐resistant P. aeruginosa or A. baumannii in pediatric patients. |
| doi_str_mv | 10.1111/j.1442-200X.2009.03015.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_748969517</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>748969517</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5185-40f408db5805ccb86f68d65fecc1b52b05aab00fa2a555b79e9b9a766de308093</originalsourceid><addsrcrecordid>eNqNkUtv1DAURi0EoqXwF5DFhlXS6_gRe8ECpqUtKg-pRWVnOYlDPeSF7YiZf4_TaWfRVb24vtI935XsgxAmkJN0jtc5YazICoBfeSoqBwqE55tn6HA_eJ56WshMgigP0KsQ1gAgS8leooM0B0oYOUTXq7FzIbrexlsTLQ5j4-Yex1vrzbTF7ehxP3fRNX7-nXkbEmuGiF0Yu4QH7AY82caZ6F2NJxOdHWJ4jV60pgv2zf19hH5-Pr1enWeX388uVh8vs5oTyTMGLQPZVFwCr-tKilbIRvDW1jWpeFEBN6YCaE1hOOdVqayqlCmFaCwFCYoeofe7vZMf_842RN27UNuuM4Md56BLJpVQnJRPIJkoOKEske8eketx9kN6hubpz4hSRCZI7qDajyF42-rJu974rSagF0N6rRcRehGxFKXvDOlNir693z9XvW32wQclCfiwA_65zm6fvFj_OD1ZupTPdvmkym72eeP_aFHSkuubb2f65OvVzZcr-kkT-h8YE67y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>503119918</pqid></control><display><type>article</type><title>Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Celebi, Solmaz ; Hacimustafaoglu, Mustafa ; Koksal, Nilgun ; Ozkan, Hilal ; Çetinkaya, Merih</creator><creatorcontrib>Celebi, Solmaz ; Hacimustafaoglu, Mustafa ; Koksal, Nilgun ; Ozkan, Hilal ; Çetinkaya, Merih</creatorcontrib><description>Aim: The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug‐resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children.
Methods: Pediatric patients hospitalized at the Uludag University Hospital who had nosocomial infections caused by multidrug‐resistant P. aeruginosa or A. baumannii, were enrolled in the study. Colistimethate sodium at a dosage of 50–75 × 103 U/kg per day was given i.v. divided into three doses.
Results: Fifteen patients received 17 courses of colistimethate sodium for the following infections: ventilator‐associated pneumonia (n= 14), catheter‐related sepsis (n= 1) and skin and soft‐tissue infection (n= 2). The mean age of patients was 53.2 + 74.7 months (range, 8 days–15 years) and 60% were male. Mortality was 26.6%.
Conclusion: Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug‐resistant P. aeruginosa or A. baumannii in pediatric patients.</description><identifier>ISSN: 1328-8067</identifier><identifier>EISSN: 1442-200X</identifier><identifier>DOI: 10.1111/j.1442-200X.2009.03015.x</identifier><identifier>PMID: 20003141</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>Acinetobacter baumannii ; Acinetobacter baumannii - drug effects ; Acinetobacter baumannii - isolation & purification ; Acinetobacter Infections - diagnosis ; Acinetobacter Infections - drug therapy ; Adolescent ; Child ; Child, Preschool ; children ; colistimethate sodium ; Colistin - analogs & derivatives ; Colistin - pharmacology ; Colistin - therapeutic use ; Cross Infection - drug therapy ; Cross Infection - microbiology ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug resistance ; Drug Resistance, Multiple, Bacterial ; Drug therapy ; Effectiveness ; Female ; Follow-Up Studies ; Hospitals, University ; Humans ; Infant ; Infant, Newborn ; Infections ; Injections, Intravenous ; Intensive Care Units, Neonatal ; Intensive Care Units, Pediatric ; Male ; Microbial Sensitivity Tests ; Neonates ; Nosocomial infection ; Pediatrics ; Prospective Studies ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - isolation & purification ; Pseudomonas Infections - diagnosis ; Pseudomonas Infections - drug therapy ; Sodium ; Statistics, Nonparametric ; Treatment Outcome ; Turkey</subject><ispartof>Pediatrics international, 2010-06, Vol.52 (3), p.410-414</ispartof><rights>2010 Japan Pediatric Society</rights><rights>Journal compilation © 2010 Japan Pediatric Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5185-40f408db5805ccb86f68d65fecc1b52b05aab00fa2a555b79e9b9a766de308093</citedby><cites>FETCH-LOGICAL-c5185-40f408db5805ccb86f68d65fecc1b52b05aab00fa2a555b79e9b9a766de308093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1442-200X.2009.03015.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1442-200X.2009.03015.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20003141$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Celebi, Solmaz</creatorcontrib><creatorcontrib>Hacimustafaoglu, Mustafa</creatorcontrib><creatorcontrib>Koksal, Nilgun</creatorcontrib><creatorcontrib>Ozkan, Hilal</creatorcontrib><creatorcontrib>Çetinkaya, Merih</creatorcontrib><title>Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients</title><title>Pediatrics international</title><addtitle>Pediatr Int</addtitle><description>Aim: The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug‐resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children.
Methods: Pediatric patients hospitalized at the Uludag University Hospital who had nosocomial infections caused by multidrug‐resistant P. aeruginosa or A. baumannii, were enrolled in the study. Colistimethate sodium at a dosage of 50–75 × 103 U/kg per day was given i.v. divided into three doses.
Results: Fifteen patients received 17 courses of colistimethate sodium for the following infections: ventilator‐associated pneumonia (n= 14), catheter‐related sepsis (n= 1) and skin and soft‐tissue infection (n= 2). The mean age of patients was 53.2 + 74.7 months (range, 8 days–15 years) and 60% were male. Mortality was 26.6%.
Conclusion: Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug‐resistant P. aeruginosa or A. baumannii in pediatric patients.</description><subject>Acinetobacter baumannii</subject><subject>Acinetobacter baumannii - drug effects</subject><subject>Acinetobacter baumannii - isolation & purification</subject><subject>Acinetobacter Infections - diagnosis</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Adolescent</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>children</subject><subject>colistimethate sodium</subject><subject>Colistin - analogs & derivatives</subject><subject>Colistin - pharmacology</subject><subject>Colistin - therapeutic use</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - microbiology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Drug therapy</subject><subject>Effectiveness</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hospitals, University</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infections</subject><subject>Injections, Intravenous</subject><subject>Intensive Care Units, Neonatal</subject><subject>Intensive Care Units, Pediatric</subject><subject>Male</subject><subject>Microbial Sensitivity Tests</subject><subject>Neonates</subject><subject>Nosocomial infection</subject><subject>Pediatrics</subject><subject>Prospective Studies</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - isolation & purification</subject><subject>Pseudomonas Infections - diagnosis</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Sodium</subject><subject>Statistics, Nonparametric</subject><subject>Treatment Outcome</subject><subject>Turkey</subject><issn>1328-8067</issn><issn>1442-200X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1DAURi0EoqXwF5DFhlXS6_gRe8ECpqUtKg-pRWVnOYlDPeSF7YiZf4_TaWfRVb24vtI935XsgxAmkJN0jtc5YazICoBfeSoqBwqE55tn6HA_eJ56WshMgigP0KsQ1gAgS8leooM0B0oYOUTXq7FzIbrexlsTLQ5j4-Yex1vrzbTF7ehxP3fRNX7-nXkbEmuGiF0Yu4QH7AY82caZ6F2NJxOdHWJ4jV60pgv2zf19hH5-Pr1enWeX388uVh8vs5oTyTMGLQPZVFwCr-tKilbIRvDW1jWpeFEBN6YCaE1hOOdVqayqlCmFaCwFCYoeofe7vZMf_842RN27UNuuM4Md56BLJpVQnJRPIJkoOKEske8eketx9kN6hubpz4hSRCZI7qDajyF42-rJu974rSagF0N6rRcRehGxFKXvDOlNir693z9XvW32wQclCfiwA_65zm6fvFj_OD1ZupTPdvmkym72eeP_aFHSkuubb2f65OvVzZcr-kkT-h8YE67y</recordid><startdate>201006</startdate><enddate>201006</enddate><creator>Celebi, Solmaz</creator><creator>Hacimustafaoglu, Mustafa</creator><creator>Koksal, Nilgun</creator><creator>Ozkan, Hilal</creator><creator>Çetinkaya, Merih</creator><general>Blackwell Publishing Asia</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>201006</creationdate><title>Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients</title><author>Celebi, Solmaz ; Hacimustafaoglu, Mustafa ; Koksal, Nilgun ; Ozkan, Hilal ; Çetinkaya, Merih</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5185-40f408db5805ccb86f68d65fecc1b52b05aab00fa2a555b79e9b9a766de308093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acinetobacter baumannii</topic><topic>Acinetobacter baumannii - drug effects</topic><topic>Acinetobacter baumannii - isolation & purification</topic><topic>Acinetobacter Infections - diagnosis</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Adolescent</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>children</topic><topic>colistimethate sodium</topic><topic>Colistin - analogs & derivatives</topic><topic>Colistin - pharmacology</topic><topic>Colistin - therapeutic use</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - microbiology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Drug therapy</topic><topic>Effectiveness</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hospitals, University</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infections</topic><topic>Injections, Intravenous</topic><topic>Intensive Care Units, Neonatal</topic><topic>Intensive Care Units, Pediatric</topic><topic>Male</topic><topic>Microbial Sensitivity Tests</topic><topic>Neonates</topic><topic>Nosocomial infection</topic><topic>Pediatrics</topic><topic>Prospective Studies</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - isolation & purification</topic><topic>Pseudomonas Infections - diagnosis</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Sodium</topic><topic>Statistics, Nonparametric</topic><topic>Treatment Outcome</topic><topic>Turkey</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Celebi, Solmaz</creatorcontrib><creatorcontrib>Hacimustafaoglu, Mustafa</creatorcontrib><creatorcontrib>Koksal, Nilgun</creatorcontrib><creatorcontrib>Ozkan, Hilal</creatorcontrib><creatorcontrib>Çetinkaya, Merih</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Celebi, Solmaz</au><au>Hacimustafaoglu, Mustafa</au><au>Koksal, Nilgun</au><au>Ozkan, Hilal</au><au>Çetinkaya, Merih</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients</atitle><jtitle>Pediatrics international</jtitle><addtitle>Pediatr Int</addtitle><date>2010-06</date><risdate>2010</risdate><volume>52</volume><issue>3</issue><spage>410</spage><epage>414</epage><pages>410-414</pages><issn>1328-8067</issn><eissn>1442-200X</eissn><abstract>Aim: The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug‐resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children.
Methods: Pediatric patients hospitalized at the Uludag University Hospital who had nosocomial infections caused by multidrug‐resistant P. aeruginosa or A. baumannii, were enrolled in the study. Colistimethate sodium at a dosage of 50–75 × 103 U/kg per day was given i.v. divided into three doses.
Results: Fifteen patients received 17 courses of colistimethate sodium for the following infections: ventilator‐associated pneumonia (n= 14), catheter‐related sepsis (n= 1) and skin and soft‐tissue infection (n= 2). The mean age of patients was 53.2 + 74.7 months (range, 8 days–15 years) and 60% were male. Mortality was 26.6%.
Conclusion: Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug‐resistant P. aeruginosa or A. baumannii in pediatric patients.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>20003141</pmid><doi>10.1111/j.1442-200X.2009.03015.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1328-8067 |
| ispartof | Pediatrics international, 2010-06, Vol.52 (3), p.410-414 |
| issn | 1328-8067 1442-200X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_748969517 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acinetobacter baumannii Acinetobacter baumannii - drug effects Acinetobacter baumannii - isolation & purification Acinetobacter Infections - diagnosis Acinetobacter Infections - drug therapy Adolescent Child Child, Preschool children colistimethate sodium Colistin - analogs & derivatives Colistin - pharmacology Colistin - therapeutic use Cross Infection - drug therapy Cross Infection - microbiology Dose-Response Relationship, Drug Drug Administration Schedule Drug resistance Drug Resistance, Multiple, Bacterial Drug therapy Effectiveness Female Follow-Up Studies Hospitals, University Humans Infant Infant, Newborn Infections Injections, Intravenous Intensive Care Units, Neonatal Intensive Care Units, Pediatric Male Microbial Sensitivity Tests Neonates Nosocomial infection Pediatrics Prospective Studies Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - isolation & purification Pseudomonas Infections - diagnosis Pseudomonas Infections - drug therapy Sodium Statistics, Nonparametric Treatment Outcome Turkey |
| title | Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A58%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Colistimethate%20sodium%20therapy%20for%20multidrug-resistant%20isolates%20in%20pediatric%20patients&rft.jtitle=Pediatrics%20international&rft.au=Celebi,%20Solmaz&rft.date=2010-06&rft.volume=52&rft.issue=3&rft.spage=410&rft.epage=414&rft.pages=410-414&rft.issn=1328-8067&rft.eissn=1442-200X&rft_id=info:doi/10.1111/j.1442-200X.2009.03015.x&rft_dat=%3Cproquest_cross%3E748969517%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=503119918&rft_id=info:pmid/20003141&rfr_iscdi=true |